相关实验视频

Updated: May 5, 2026

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

在基于树突细胞的瘤免疫疗法中探索Clec9a,以获得分子洞察力和治疗潜力

Zubair Hussain^1,2,3,4, Yueteng Zhang¹, Lu Qiu⁵

¹Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China.

|February 7, 2025

概括

1型常规树突细胞 (cDC1s) 对于瘤免疫疗法至关重要. 在cDC1s上的C型乳素受体Clec9a (DNGR-1) 增强了抗瘤免疫力,并减少了副作用,使其成为一个有前途的目标.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
细胞生物学细胞生物学

背景情况:

1型常规树突细胞 (cDC1s) 对于瘤免疫疗法至关重要,因为它们具有抗原交叉呈现和免疫调节能力.
C型乳清受体Clec9a (也称为DNGR-1) 仅在cDC1s上表达,并在它们的功能中发挥关键作用.

研究的目的:

审查Clec9a.的分子特征,表达和信号.
探索Clec9a在cDC1激活中的作用及其增强抗瘤免疫力的潜力.
讨论针对Clec9a的策略,以提高瘤疫苗的疗效和减少不良影响.

主要方法:

文献综述侧重于cDC1s中的Clec9a功能.
分析Clec9a在抗原交叉呈现和T细胞反应中的作用.
探索Clec9a作为药物输送和疫苗增强的目标.

主要成果:

Clec9a增强了cDC1介导的抗原交叉呈现和细胞毒性T淋巴细胞 (CTL) 反应.
激活Clec9a可以减轻非目标效应,包括自身免疫反应和全身炎症.
Clec9a促进了死细胞相关抗原的交叉呈现,改善了抗瘤免疫力.

结论:

基于树突细胞的瘤免疫治疗中,Clec9a是一个有前途的标.
向Clec9a可以提高疫苗的免疫性和治疗疗效,同时最大限度地降低毒性.
针对Clec9a的激动剂,如STING激动剂和αGC,提供了一种新的方法来促进抗瘤反应.

更多相关视频

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.